Cargando…

Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial

BACKGROUND: Early treatment of COVID-19 patients could reduce hospitalization and death. The effect of corticosteroids in the outpatient setting is still unknown. This study aimed to determine the effect of corticosteroids in the prevention of hospitalization of nonsevere cases. MATERIALS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Amra, Babak, Vaezi, Atefeh, Soltaninejad, Forogh, Salahi, Mehrdad, Salmasi, Mehrzad, Haghjooy Javanmard, Shaghayegh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331530/
https://www.ncbi.nlm.nih.gov/pubmed/37434926
http://dx.doi.org/10.4103/abr.abr_72_22
_version_ 1785070273302626304
author Amra, Babak
Vaezi, Atefeh
Soltaninejad, Forogh
Salahi, Mehrdad
Salmasi, Mehrzad
Haghjooy Javanmard, Shaghayegh
author_facet Amra, Babak
Vaezi, Atefeh
Soltaninejad, Forogh
Salahi, Mehrdad
Salmasi, Mehrzad
Haghjooy Javanmard, Shaghayegh
author_sort Amra, Babak
collection PubMed
description BACKGROUND: Early treatment of COVID-19 patients could reduce hospitalization and death. The effect of corticosteroids in the outpatient setting is still unknown. This study aimed to determine the effect of corticosteroids in the prevention of hospitalization of nonsevere cases. MATERIALS AND METHODS: This study is a multicenter randomized controlled trial. Seventy five nonsevere COVID-19 patients presented between days 7 and 14 of their symptoms received either prednisolone or placebo. The primary outcome was hospitalization. The study protocol was registered in the Iranian Registry of Clinical Trials on December 2, 2020 (IRCT20171219037964N2). RESULTS: Although the rate of hospitalization in the prednisolone group was higher than the placebo group (10.8% vs. 7.9%, respectively), it was not statistically significant (P value.,6). One patient in each group reported an adverse event and withdrew the medication. CONCLUSION: Considering the null effect of corticosteroids in the prevention of hospitalization in outpatient settings, it is suggested not to consider corticosteroids for outpatient treatment.
format Online
Article
Text
id pubmed-10331530
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-103315302023-07-11 Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial Amra, Babak Vaezi, Atefeh Soltaninejad, Forogh Salahi, Mehrdad Salmasi, Mehrzad Haghjooy Javanmard, Shaghayegh Adv Biomed Res Original Article BACKGROUND: Early treatment of COVID-19 patients could reduce hospitalization and death. The effect of corticosteroids in the outpatient setting is still unknown. This study aimed to determine the effect of corticosteroids in the prevention of hospitalization of nonsevere cases. MATERIALS AND METHODS: This study is a multicenter randomized controlled trial. Seventy five nonsevere COVID-19 patients presented between days 7 and 14 of their symptoms received either prednisolone or placebo. The primary outcome was hospitalization. The study protocol was registered in the Iranian Registry of Clinical Trials on December 2, 2020 (IRCT20171219037964N2). RESULTS: Although the rate of hospitalization in the prednisolone group was higher than the placebo group (10.8% vs. 7.9%, respectively), it was not statistically significant (P value.,6). One patient in each group reported an adverse event and withdrew the medication. CONCLUSION: Considering the null effect of corticosteroids in the prevention of hospitalization in outpatient settings, it is suggested not to consider corticosteroids for outpatient treatment. Wolters Kluwer - Medknow 2023-05-15 /pmc/articles/PMC10331530/ /pubmed/37434926 http://dx.doi.org/10.4103/abr.abr_72_22 Text en Copyright: © 2023 Advanced Biomedical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Amra, Babak
Vaezi, Atefeh
Soltaninejad, Forogh
Salahi, Mehrdad
Salmasi, Mehrzad
Haghjooy Javanmard, Shaghayegh
Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial
title Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial
title_full Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial
title_fullStr Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial
title_full_unstemmed Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial
title_short Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial
title_sort steroid in the treatment of outpatient covid-19: a multicenter randomized controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331530/
https://www.ncbi.nlm.nih.gov/pubmed/37434926
http://dx.doi.org/10.4103/abr.abr_72_22
work_keys_str_mv AT amrababak steroidinthetreatmentofoutpatientcovid19amulticenterrandomizedcontrolledtrial
AT vaeziatefeh steroidinthetreatmentofoutpatientcovid19amulticenterrandomizedcontrolledtrial
AT soltaninejadforogh steroidinthetreatmentofoutpatientcovid19amulticenterrandomizedcontrolledtrial
AT salahimehrdad steroidinthetreatmentofoutpatientcovid19amulticenterrandomizedcontrolledtrial
AT salmasimehrzad steroidinthetreatmentofoutpatientcovid19amulticenterrandomizedcontrolledtrial
AT haghjooyjavanmardshaghayegh steroidinthetreatmentofoutpatientcovid19amulticenterrandomizedcontrolledtrial